Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, announced that the company has entered into a USD 160m revenue interest purchase and sale agreement for its investigational product tapinarof with three participants that include Marathon Asset Management, NovaQuest Capital Management and a third institutional investor located in Boston. The company concurrently entered into a USD 40m senior secured credit facility with the Boston-based firm. Tapinarof is a novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically elegant topical cream being investigated for the treatment of plaque psoriasis and atopic dermatitis.
VISCHER acted as Swiss counsel to Dermavant in the transaction. The team was led by Adrian Dörig (Partner, Banking & Finance) with Ruben Masar (Senior Associate) and Sebastian Flückiger (Associate) (both Corporate Finance), Delia Fehr-Bosshard (Managing Associate, Intellectual Property) and Christoph Niederer (Partner) and Patrik Fisch (Associate) (both Tax).
Ruben Masar
Attorney at Law, Honorary Consul of the Slovak Republic
- Partner
- +41 58 211 33 38
- [email protected]
Christoph Niederer
Attorney at Law, Swiss Certified Tax Expert
- Partner
- +41 58 211 34 37
- [email protected]
